Suppr超能文献

使用终末期肝病模型(MELD)评分来预测日本肝硬化患者的1年生存率,并确定谁将从活体肝移植中获益。

Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation.

作者信息

Ishigami Masatoshi, Honda Takashi, Okumura Akihiko, Ishikawa Tetsuya, Kobayashi Makoto, Katano Yoshiaki, Fujimoto Yasuhiro, Kiuchi Tetsuya, Goto Hidemi

机构信息

Department of Gastroenterology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.

出版信息

J Gastroenterol. 2008;43(5):363-8. doi: 10.1007/s00535-008-2168-7. Epub 2008 Jul 1.

Abstract

BACKGROUND

Consideration of the prognosis of patients with liver cirrhosis is important when determining the appropriate timing of liver transplantation. Especially in Japan, where 99% of liver transplants are from living donors, timing is very important not only for the patient but also for the family, who need time to consider the various factors involved in living donations.

METHODS

To clarify the applicability of the Model for End-Stage Liver Disease (MELD) score in Japanese patients with cirrhosis, changes in the MELD score over 24 months were reviewed in 79 patients with cirrhosis who subsequently died of liver failure (n=33) or who survived 24 months (n=46). All patients had Child class B or C cirrhosis at the start of follow-up. We also compared their survival with that of 30 patients treated by living donor liver transplantation (LDLT) in our institute to determine the proper timing of transplantation in patients with cirrhosis.

RESULTS

Significant stratification of survival curves was observed for MELD scores of <12, 12-15, 15-18, and >18 (P=0.0018). A significant survival benefit of LDLT was observed in patients with MELD score >or=15 (P=0.0181), and significantly more risk with transplantation was observed in those with MELD score <15 compared with that of patients in whom the disease followed its natural course (P=0.0168).

CONCLUSIONS

MELD score is useful for predicting 1-year survival in Japanese patients with cirrhosis. MELD scores of 15 had discriminatory value for indicating a survival benefit to be gained by liver transplantation and thus can be used to help patients and their families by identifying patients who would benefit from LDLT.

摘要

背景

在确定肝移植的合适时机时,考虑肝硬化患者的预后很重要。特别是在日本,99%的肝移植来自活体供体,时机不仅对患者很重要,对其家属也很重要,因为家属需要时间来考虑活体捐赠所涉及的各种因素。

方法

为了阐明终末期肝病模型(MELD)评分在日本肝硬化患者中的适用性,我们回顾了79例肝硬化患者在24个月内MELD评分的变化情况,这些患者随后死于肝衰竭(n = 33)或存活了24个月(n = 46)。所有患者在随访开始时均为Child B级或C级肝硬化。我们还将他们的生存率与我院30例接受活体供肝移植(LDLT)治疗的患者进行比较,以确定肝硬化患者移植的合适时机。

结果

MELD评分<12、12 - 15、15 - 18和>18时,生存曲线出现显著分层(P = 0.0018)。MELD评分≥15的患者接受LDLT有显著的生存获益(P = 0.0181),与疾病自然进展的患者相比,MELD评分<15的患者移植风险显著更高(P = 0.0168)。

结论

MELD评分有助于预测日本肝硬化患者的1年生存率。MELD评分为15对表明肝移植可获得的生存获益具有鉴别价值,因此可用于帮助患者及其家属识别将从LDLT中获益的患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验